NCT06389552Active, not recruiting
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 36 (estimated)
- First submitted
- 24 Apr 2024
- Start date
- 25 Sept 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- HK inno.N Corporation
- Diseases
- Pancreatic cancer
- NCT number
- NCT06389552
What you commit to
- Study type: Observational
- Planned participants: 36
- From 25 Sept 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- FOLFIRINOX contraindications among the drug approval requirements
- Palliative Therapy
Other illness
- Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
Who the study is looking for
- Age over 19 at the time of obtaining the informed consent form
- Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- ECOG 0 or 1
- Scheduled to RO or R1 resection
- Organ function capable of chemotherapy
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.